Related Experiment Video
Updated: Aug 7, 2026
Culture of Bladder Cancer Organoids as Precision Medicine Tools
Published on: December 28, 2021
Molecular biology of bladder cancer: prognostic and clinical implications
Anirban P Mitra1, Henry Lin, Ram H Datar
1Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA.
Abstract:
The role of various molecular determinants involved in the genesis, progression, and outcome of bladder cancer has been the focus of investigations for the past 2 decades. Increasingly, the analysis of the interplay between these molecular factors is taking center stage. We review herein the studies examining the effects of deregulation of the various molecules implicated in the cell cycle, apoptosis, and angiogenesis pathways and analyze the central role of p53 in regulating these pathways. Technological advancements enable detection and quantification of gene transcripts and protein products, helping us move toward achieving the goal of establishing diagnostic, prognostic, and therapeutic marker panels. Recent studies have therefore focused on multiple-marker analyses to generate informative panels that can have greater clinical value for bladder cancer management. The use of molecular marker panels can provide a more objective alternative to clinical parameters for diagnosis and treatment decisions. Clinical trials aimed at treating urothelial carcinoma based on a patient's molecular profile can be predicted to empower clinicians to personalize patient management through increased therapeutic efficacy.
Insights
Molecular markers are key to understanding bladder cancer progression and outcomes. Analyzing these markers, especially p53, helps develop diagnostic and prognostic panels for personalized urothelial carcinoma treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Bladder cancer research has focused on molecular determinants for two decades.
- Interplay between molecular factors is increasingly central to understanding cancer.
- Deregulation of cell cycle, apoptosis, and angiogenesis pathways are implicated in bladder cancer.
Purpose of the Study:
- To review studies on molecular determinants in bladder cancer.
- To analyze the role of p53 in regulating key cancer pathways.
- To highlight the clinical value of molecular marker panels for bladder cancer management.
Main Methods:
- Review of existing scientific literature on molecular markers in bladder cancer.
- Analysis of studies examining deregulation of cell cycle, apoptosis, and angiogenesis.
- Evaluation of the role of p53 in regulating these pathways.
Main Results:
- Molecular factors significantly influence bladder cancer genesis, progression, and outcome.
- p53 plays a central role in regulating cell cycle, apoptosis, and angiogenesis pathways.
- Technological advancements facilitate the development of molecular marker panels.
Conclusions:
- Molecular marker panels offer objective alternatives to clinical parameters for diagnosis and treatment.
- Personalized urothelial carcinoma treatment based on molecular profiles can enhance therapeutic efficacy.
- Future clinical trials will focus on molecular profiling for tailored patient management.
